Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.
The new oral neuraminidase (NA) inhibitor A-322278 was evaluated in mice infected with influenza A/H1N1 wild-type virus or the oseltamivir-resistant (H274Y mutant) virus. A-322278 decreased mortality rates and lung virus titers significantly more than oseltamivir in mice infected with the NA H274Y mutant when therapy was started 4 h before or even 48 h after infection.
Baz
Mariana
M
Research Center in Infectious Diseases, CHUQ-CHUL, Laval University, Québec City, Canada.
Abed
Yacine
Y
Nehmé
Benjamin
B
Boivin
Guy
G
D000818:Animals; D025141:Drug Resistance, Fungal / Q000187:drug effects / Q000235:genetics; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000235:genetics*; D008168:Lung / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation / Q000235:genetics; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D009976:Orthomyxoviridae Infections / Q000188:drug therapy / Q000401:mortality / Q000821:virology; D053139:Oseltamivir / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019562:Viral Load
C510679:A-322278; D011759:Pyrrolidines; D053139:Oseltamivir; D009439:Neuraminidase